Literature DB >> 19797521

Abnormal serum free light chain ratio in patients with multiple myeloma in complete remission has strong association with the presence of oligoclonal bands: implications for stringent complete remission definition.

Carlos Fernández de Larrea1, María Teresa Cibeira, Montserrat Elena, Juan Ignacio Arostegui, Laura Rosiñol, Montserrat Rovira, Xavier Filella, Jordi Yagüe, Joan Bladé.   

Abstract

The prevalence of an abnormal serum free light chain (FLC) ratio in 34 patients with multiple myeloma in complete response (CR) after hematopoietic stem cell transplantation was studied. Fourteen of 34 patients (41.2%) showed an abnormal FLC ratio. The frequency of abnormal FLC ratio in patients with or without oligoclonal bands was 72.7% versus 26%, respectively (P = .023). The median value of FLC ratio was 2.55 (95% confidence interval, 1.89-3.20) in patients with oligoclonal bands versus 0.87 (95% confidence interval, 0.70-1.04) for those with no oligoclonal bands (P = .011). This is the first report showing that the presence of oligoclonal bands in patients with multiple myeloma in CR frequently results in an abnormal FLC ratio. Because an oligoclonal immune response is associated with a good outcome, our results question the current definition of stringent CR and support that the prognostic impact of oligoclonal bands should be also assessed on multivariate analysis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19797521     DOI: 10.1182/blood-2009-06-224832

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  13 in total

1.  Emergence of oligoclonal bands in patients with multiple myeloma in complete remission after induction chemotherapy: association with the use of novel agents.

Authors:  Carlos Fernández de Larrea; Natalia Tovar; M Teresa Cibeira; Juan I Aróstegui; Laura Rosiñol; Montserrat Elena; Xavier Filella; Jordi Yagüe; Joan Bladé
Journal:  Haematologica       Date:  2010-09-30       Impact factor: 9.941

Review 2.  Minimal residual disease testing after stem cell transplantation for multiple myeloma.

Authors:  A M Sherrod; P Hari; C A Mosse; R C Walker; R F Cornell
Journal:  Bone Marrow Transplant       Date:  2015-07-20       Impact factor: 5.483

Review 3.  New criteria for response assessment: role of minimal residual disease in multiple myeloma.

Authors:  Bruno Paiva; Jacques J M van Dongen; Alberto Orfao
Journal:  Blood       Date:  2015-04-02       Impact factor: 22.113

4.  Defining the impact of individual sample variability on routine immunoassay of serum free light chains (sFLC) in multiple myeloma.

Authors:  S H K Murng; L Follows; P Whitfield; J A Snowden; K Swallow; K Green; R Sargur; W Egner
Journal:  Clin Exp Immunol       Date:  2013-02       Impact factor: 4.330

5.  Critical analysis of the stringent complete response in multiple myeloma: contribution of sFLC and bone marrow clonality.

Authors:  Joaquín Martínez-López; Bruno Paiva; Lucía López-Anglada; María-Victoria Mateos; Teresa Cedena; María-Belén Vidríales; María Auxiliadora Sáez-Gómez; Teresa Contreras; Albert Oriol; Inmaculada Rapado; Ana-Isabel Teruel; Lourdes Cordón; María Jesús Blanchard; Enrique Bengoechea; Luis Palomera; Felipe de Arriba; Cecilia Cueto-Felgueroso; Alberto Orfao; Joan Bladé; Jesús F San Miguel; Juan José Lahuerta
Journal:  Blood       Date:  2015-06-18       Impact factor: 22.113

6.  Emergence of Oligoclonal Bands in Association with the use of Chemotherapy and Hematopoietic Stem Cell Transplantation.

Authors:  Chandramallika Paul; Sarit Chakraborty; Subhosmito Chakraborty
Journal:  Indian J Clin Biochem       Date:  2021-05-19

Review 7.  Risk Stratification in Multiple Myeloma.

Authors:  Melissa Gaik-Ming Ooi; Sanjay de Mel; Wee Joo Chng
Journal:  Curr Hematol Malig Rep       Date:  2016-04       Impact factor: 3.952

8.  Secondary monoclonal gammopathy of undetermined significance after allogeneic stem cell transplantation in multiple myeloma.

Authors:  Marian F Schmitz; Henny G Otten; Laurens E Franssen; Suzanne van Dorp; Theo Strooisma; Henk M Lokhorst; Niels W C J van de Donk
Journal:  Haematologica       Date:  2014-09-05       Impact factor: 9.941

9.  Natural history and prognostic impact of oligoclonal humoral response in patients with multiple myeloma after autologous stem cell transplantation: long-term results from a single institution.

Authors:  Natalia Tovar; Carlos Fernández de Larrea; Juan I Aróstegui; Maria Teresa Cibeira; Laura Rosiñol; Montserrat Rovira; Montserrat Elena; Xavier Filella; Jordi Yagüe; Joan Bladé
Journal:  Haematologica       Date:  2013-05-03       Impact factor: 9.941

10.  Comparative analysis of minimal residual disease detection by multiparameter flow cytometry and enhanced ASO RQ-PCR in multiple myeloma.

Authors:  R Silvennoinen; T Lundan; V Kairisto; T-T Pelliniemi; M Putkonen; P Anttila; V Huotari; P Mäntymaa; S Siitonen; L Uotila; T-L Penttilä; V Juvonen; T Selander; K Remes
Journal:  Blood Cancer J       Date:  2014-10-10       Impact factor: 11.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.